INTRODUCCIÓN WP2

Interventional and strategic Studies addressed to minimize the impact of toxicity of ART, IRIS, and aids and non-aids events

Asset Publisher

RIS-EST53. ELAVI67 Study.

Assessment of the efficacy of biomarker mRNA-E6/E7 in the detection of high grade injuries and cost-effectiveness analysis of a new anal cancer screening algorithm in men who have sex with HIV men. 
 

Leader Researcher: Daniel Podzamczer, Ana Silva.

Sponsor: IDIBELL-Hospital Universitari de Bellvitge.

Status: Ongoing.

RIS-EST52. ELAVI Study.

Study to assess incidence, progression and/or regression of anal injuries associated to HPV in an HIV positive homosexual population. 
 

Leader Researcher: Daniel Podzamczer, María Saumoy.

Sponsor: IDIBELL-Hospital Universitari de Bellvitge.

Status: Ongoing.

RIS-EST51. ATERISC Study.

Study to assess prevalence of subclinic carotid arteriosclerosis and cardiovascular risk factors in HIV patients and the connection of this variable with cardiovascular events and mortality. 
 

Leader Researcher: Daniel Podzamczer, María Saumoy.

Sponsor: IDIBELL-Hospital Universitari de Bellvitge.

Status: Completed.

RIS-EST49. STRIB-PEP Study.

Study to compare two different drug combinations for HIV post-exposure prophylaxis: Tenofovir/Emtricitabina (Truvada®) + Lopinavir/Ritonavir (Kaletra®) vs Tenofovir/Emtricitabina/Cobicistat/Elvitegravir (Stribild®).
 

Leader Researcher: Felipe García.

Sponsor: Fundació Clínic Recerca Biomédica.

Status: Completed.

RIS-EST33. PATHER Study.

Study to assess inflammatory markers and analyse LDL and HDL cholesterol particles in the atherosclerotic disease pathogenesis in HIV infected patients.

Leader Researcher: Daniel Podzamczer, María Saumoy.

Sponsor: IDIBELL-Hospital Universitari de Bellvitge.

Status: Completed.

RIS-EST44. VITD Study.

Assessment the influence of vitamin D supplement in the progression of arteriosclerosis in virologically supresed HIV patients.
 

Leader Researcher: Mar Masià.

Sponsor: Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO).

Status: Recruiting.

RIS-EST32. CARIOCA-trans Study.

Cross-sectional study to assess cardiovascular risk in HIV patients after 2 years of an intensive and multidisciplinary intervention of lifestyle habits.    
 

Leader Researcher: Daniel Podzamczer.

Sponsor: IDIBELL-Hospital Universitari de Bellvitge.

Status: Completed.

RIS-EST27. APACHE Study.

Evolution of brain functioning and neurocognitive performance in previously untreated HIV infected patients after 24 weeks of two highly active antiretroviral therapy regimens with different absorption levels in the central nervous system.  
 

Leader Researcher: José R. Arribas.

Sponsor: Fundacion para la Investigación Biomédica del Hospital Universitario La Paz.

Status: Completed.